Two Immunotherapy Drugs Better than One for Head and Neck Cancer

Two Immunotherapy Drugs Better than One for Head and Neck Cancer

Source: Inside Precision Medicine

A Phase II trial has shown that adding an extra immunotherapy drug to monotherapy treatment can improve the survival of patients with head and neck cancer and also offer biological signposts to individualized treatments.

Adding an extra immunotherapy drug to single-drug treatment for head and neck cancer could shrink tumor size further and improve survival, trial findings suggest, as well as offer biological markers for how to best personalize treatment.
The Phase II… [3059 chars]

Read more